Telomir Pharmaceuticals Stock Soars Over 90% On Positive Preclinical Data

(RTTNews) - Telomir Pharmaceuticals, Inc. (TELO) surged 90.08 percent to $2.30 on Friday after announcing promising preclinical results for its lead candidate, Telomir-1.

TELO opened at $3.05 and traded between $2.04 and $3.10, with volume skyrocketing to 116.5 million shares compared to an average of 600,831 on the Nasdaq. The stock's 52-week range is $1.12 to $8.40, and its previous close was $1.21.

The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of the STAT1 tumor suppressor in aggressive human prostate cancer cells, outperforming both Paclitaxel and Rapamycin.

The findings suggest Telomir-1 could restore immune surveillance and programmed cell death functions in advanced cancers, where STAT1 is often silenced through promoter hypermethylation. The compound achieved full reversal of hypermethylation in a dose-dependent manner during a 21-day oral treatment in a PC3 xenograft mouse model.